Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
-192.40M | -84.66M | -31.48M | -18.73M | -2.94M | EBITDA |
-192.40M | -84.66M | -31.48M | 0.00 | 0.00 | Net Income Common Stockholders |
-177.81M | -71.90M | -29.80M | -19.41M | -3.43M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
198.19M | 236.57M | 110.11M | 10.61M | 1.41M | Total Assets |
205.90M | 251.64M | 114.44M | 11.13M | 1.49M | Total Debt |
0.00 | 0.00 | 0.00 | 0.00 | 4.50M | Net Debt |
-114.09M | -49.30M | -87.70M | -10.61M | 3.09M | Total Liabilities |
14.65M | 10.48M | 166.71M | 34.05M | 5.08M | Stockholders Equity |
191.26M | 241.15M | -52.27M | -22.93M | -3.60M |
Cash Flow | Free Cash Flow | |||
-166.41M | -81.17M | -29.22M | -14.56M | -2.46M | Operating Cash Flow |
-166.31M | -81.17M | -29.22M | -14.56M | -2.46M | Investing Cash Flow |
114.96M | -160.47M | -21.76M | 0.00 | 0.00 | Financing Cash Flow |
116.14M | 203.25M | 128.02M | 23.81M | 3.83M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $970.55M | ― | -82.24% | ― | ― | -106.10% | |
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% | |
51 Neutral | $839.43M | ― | -38.09% | ― | -13.90% | 16.56% | |
46 Neutral | $1.27B | ― | -78.34% | ― | ― | -70.45% | |
43 Neutral | $883.64M | 2.31 | -42.90% | ― | -100.00% | 94.68% | |
36 Underperform | $1.01B | ― | -32.04% | ― | ― | 12.85% |
On March 29, 2025, Mineralys Therapeutics announced detailed results from the Advance-HTN pivotal trial of lorundrostat for uncontrolled and resistant hypertension. The trial demonstrated significant blood pressure reductions and a favorable safety profile, underscoring lorundrostat’s potential as a best-in-class treatment for high-risk patients. The results were presented at the American College of Cardiology’s Annual Scientific Session & Expo, highlighting lorundrostat’s clinical utility across diverse care settings and its potential impact on hypertension care.
On March 10, 2025, Mineralys Therapeutics announced positive results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials for lorundrostat, a treatment for uncontrolled or resistant hypertension. Both trials met their primary efficacy endpoints, showing statistically significant reductions in systolic blood pressure and a favorable safety profile, indicating potential for regulatory approval and commercial value.
On February 4, 2025, Mineralys Therapeutics announced the completion of enrollment for its Explore-CKD Phase 2 trial, which evaluates the efficacy and safety of lorundrostat for treating hypertension in patients with CKD and albuminuria. This trial aims to address poorly controlled hypertension, a major cause of renal failure and cardiovascular events, with results expected in the second quarter of 2025. This development marks a significant step in expanding treatment options for high-risk patients, potentially impacting the company’s competitive position in the market.